The Cleveland Clinic
A prospective observational cohort trial to study the effects of CGRP inhibitors (CGRPi) on lower urinary tract symptoms (LUTS) and bladder/pelvic pain. Candidates for either CGRPi or an alternative therapy for refractory migraines (OnabotulinumtoxinA (BoNTA) extracranial muscle injections) with baseline LUTS will be recruited. The investigators will assess LUTS and pelvic pain using validated symptom and quality-of-life questionnaires, pretreatment and at 3 months post-treatment follow-up, comparing change in symptoms based on treatment received.
Common urinary urgency syndromes may be related to over-activation of bladder afferent pathways involving CGRP signaling. CGRP (calcitonin gene related protein) is a neurotransmitter in afferent pathways also involved in central nociception and hypersensitization. CGRP-targeted therapies, approved for migraine treatment, have the potential to alleviate lower urinary tract symptoms, but these possible effects have not been studied in humans. This is a prospective observational cohort trial to study the effects of CGRP inhibitors (CGRPi) on lower urinary tract symptoms (LUTS) and bladder/pelvic…
Inclusion Criteria: * Female Patients \> 18 years * Refractory migraine, planned treatment with either: * CGRP inhibitors, including: * CGRP small molecule receptor antagonists ("gepants"): Ubrogepant, Rimegepant, Atogepant. * CGRP monoclonal antibodies: Eptinezumab, Fremanezumab, Galcanezumab. * CGRP receptor monoclonal antibodies: Erenumab. * BoNTA extracranial muscle injections * Any of the following symptoms during the last month: * Urinating too often (frequency). * Having a sudden urge to urinate that's difficult to hold back (urgency). * Having a sudden urge to urinate an…
Ubrogepant (Ubrelvy™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
Rimegepant (Nurtec®), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
Atogepant (Qulipta™), oral, dosage at discretion of clinical provider, for treatment of migraine headaches.
Eptinezumab (Vyepti®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Fremanezumab (Ajovy®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Galcanezumab (Emgality®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Erenumab (Aimovig®) injection, dosage at discretion of clinical provider, for treatment of migraine headaches.
Botolinum toxin A (Botox) injections into extracranial muscles, dosage at discretion of clinical provider, for treatment of migraines.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.